Clincosm LogoSign in Get a demo

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Sponsor
Spark Therapeutics (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT00999609
Collaborator
Children's Hospital of Philadelphia (Other), University of Iowa (Other)
31
Enrollment
2
Locations
2
Arms
201
Anticipated Duration (Months)
15.5
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl). At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with RPE65 gene mutations.

Condition or Disease Intervention/Treatment Phase
  • Biological: AAV2-hRPE65v2,voretigene neparvovec-rzyl
 Phase 3

Detailed Description

Leber congenital amaurosis (LCA) is a disease where part of the eye (the retina) is severely diseased. Usually it is detected in affected people within the first few months of life, as there is significantly poor vision at birth. Cells in the retina are lost over time in people with LCA, which typically leads to total blindness. There are no pharmacological treatments available. This study will focus on the form of LCA caused by changes (mutations) in DNA that makes a certain protein (called the 65 kDa retinal pigment epithelium (RPE)-specific protein, or RPE65). This can be confirmed by a special method of testing (molecular testing) to verify the presence of RPE65 gene mutations.

This study uses a gene therapy vector made from an adeno-associated virus (AAV) called AAV2-hRPE65v2 (voretigene neparovec-rzyl). Gene therapy refers to the incorporation of new DNA into cells with the goal of supplying a therapeutic gene or a gene that is missing or not functioning in the cell. The AAV parts of the gene therapy vector work as a delivery vehicle for providing the normal human RPE65 gene to the cells of the retina. An earlier Phase 1 clinical study of AAV2-hRPE65v2 was conducted based on the demonstration of safety and effectiveness of the vector in animals with a similar eye disease. The earlier Phase 1 clinical study was a dose-escalation study primarily designed to evaluate safety in humans, and tested three doses of the vector in twelve children and adults. The safety of injecting into the second eye was also evaluated. The results from these earlier Phase 1 studies showed an acceptable safety profile.

This study will deliver AAV2-hRPE65v2 vector (voretigene neparvovec-rzyl) to at least sixteen intervention group subjects, age three or older; subjects will receive the vector in both eyes via subretinal injections during surgeries (on separate days). The purpose of this research study is to assess the efficacy and safety of the AAV2-hRPE65v2 gene therapy vector (voretigene neparvovec-rzyl) as a possible treatment for LCA due to RPE65 gene mutations. The control group of at least eight subjects will be able to cross-over to the intervention group after one year, provided they still meet all eligibility criteria.

Study Design

Study Type:
Interventional
Actual Enrollment :
31 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]
Actual Study Start Date :
Oct 1, 2012
Actual Primary Completion Date :
Jul 1, 2015
Anticipated Study Completion Date :
Jul 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: AAV2-hRPE65v2,voretigene neparvovec-rzyl

voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart

Biological: AAV2-hRPE65v2,voretigene neparvovec-rzyl
Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
Other Names:
  • AAV2-hRPE65v2
  • voretigene neparvovec-rzyl
  • gene therapy vector

    		•
    No Intervention: Control

    No intervention

    Outcome Measures

    Primary Outcome Measures

    1. Multi-luminance Mobility Testing (MLMT), Bilateral [One year (change from baseline)]

      The MLMT measures changes in functional vision, as assessed by the ability to navigate a course accurately and at a reasonable pace at different levels of environmental illumination. MLMT was assessed using both eyes at 1 or more of 7 levels of illumination, ranging from 400 lux (a brightly lit office) to 1 lux (a moonless summer night). Each light level was assigned a score code ranging from 0 to 6. A higher score indicated that a subject was able to pass the MLMT at a lower light level. A score of -1 was assigned to those who could not pass MLMT at 400 lux. The MLMT of each subject was videotaped and assessed by independent graders. The MLMT score was determined by the lowest light level at which the subject was able to pass the MLMT. The MLMT score change was defined as the difference between the score at Baseline and the score at Year 1. A positive MLMT score change from Baseline to Year 1 visit indicated that the subject was able to complete the MLMT at a lower light level.

    Secondary Outcome Measures

    1. Full-field Light Sensitivity Threshold (FST) Testing: White Light [One year (change from baseline)]

      Measures the light sensitivity of the entire visual field by recording the luminance at which a subject reliably reports seeing the dimmest flash.

    2. Multi-luminance Mobility Testing (Monocular) [One year (change from baseline)]

      The MLMT measures changes in functional vision, as assessed by the ability to navigate a course accurately and at a reasonable pace at different levels of environmental illumination. MLMT was assessed using the first eye at 1 or more of 7 levels of illumination, ranging from 400 lux (a brightly lit office) to 1 lux (a moonless summer night). Each light level was assigned a score code ranging from 0 to 6. A higher score indicated that a subject was able to pass the MLMT at a lower light level. A score of -1 was assigned to those who could not pass MLMT at 400 lux. The MLMT of each subject was videotaped and assessed by independent graders. The MLMT score was determined by the lowest light level at which the subject was able to pass the MLMT. The MLMT score change was defined as the difference between the score at Baseline and the score at Year 1. A positive MLMT score change from Baseline to Year 1 visit indicated that the subject was able to complete the MLMT at a lower light level.

    3. Visual Acuity [One year (change from baseline)]

      Measurement of the sharpness of vision, determined by the ability to read letters on a standardized chart from a specified distance.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    3 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Willingness to adhere to protocol and long-term follow-up as evidenced by written informed consent or parental permission and subject assent (where applicable).

    • Diagnosis of LCA due to RPE65 mutations; molecular diagnosis is to be performed, or confirmed, by a CLIA-approved laboratory.

    • Age three years old or older.

    • Visual acuity worse than 20/60 (both eyes) and/or visual field less than 20 degrees in any meridian as measured by a III4e isopter or equivalent (both eyes).

    • Sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy. Must have either: 1) an area of retina within the posterior pole of >100 µm thickness shown on OCT; 2) ≥ 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or 3) remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent.

    • Subjects must be evaluable on mobility testing (the primary efficacy endpoint) to be eligible for the study. Evaluable is defined as: 1) The ability to perform mobility testing within the luminance range evaluated in the study. Individuals must receive an accuracy score of ≤ 1 during screening mobility testing at 400 lux or less to be eligible; individuals with an accuracy score of > 1 on all screening mobility test runs at 400 lux, or those who refuse to perform mobility testing at screening, will be excluded. 2) The inability to pass mobility testing at 1 lux. Individuals must fail screening mobility testing at 1 lux to be eligible; individuals that pass one or more screening mobility test runs at 1 lux will be excluded.

    Exclusion Criteria:

    • Unable or unwilling to meet requirements of the study, including receiving bilateral subretinal vector administrations.

    • Any prior participation in a study in which a gene therapy vector was administered.

    • Participation in a clinical study with an investigational drug in the past six months.

    • Use of retinoid compounds or precursors that could potentially interact with the biochemical activity of the RPE65 enzyme; individuals who discontinue use of these compounds for 18 months may become eligible.

    • Prior intraocular surgery within six months.

    • Known sensitivity to medications planned for use in the peri-operative period.

    • Pre-existing eye conditions or complicating systemic diseases that would preclude the planned surgery or interfere with the interpretation of study. Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example: radiation treatment of the orbit; leukemia with CNS/optic nerve involvement). Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g., macular edema or proliferative changes). Also excluded would be subjects with immunodeficiency (acquired or congenital) as there could be susceptibility to opportunistic infection (such as CMV retinitis).

    • Individuals of childbearing potential who are pregnant or unwilling to use effective contraception for four months following vector administration.

    • Individuals incapable of performing mobility testing (the primary efficacy endpoint) for reason other than poor vision, including physical or attentional limitations.

    • Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential subject unsuitable for the study.

    • Subjects will not be excluded based on their gender, race, or ethnicity.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Iowa Iowa City Iowa United States 52242
    2 Children's Hospital of Philadelphia Philadelphia Pennsylvania United States 19104

    Sponsors and Collaborators

    • Spark Therapeutics
    • Children's Hospital of Philadelphia
    • University of Iowa

    Investigators

    • Principal Investigator: Albert M Maguire, MD, Children's Hospital of Philadelphia
    • Principal Investigator: Stephen R Russell, MD, University of Iowa

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Spark Therapeutics
    ClinicalTrials.gov Identifier:
    NCT00999609
    Other Study ID Numbers:
    • AAV2-hRPE65v2-301
    First Posted:
    Oct 22, 2009
    Last Update Posted:
    Dec 13, 2021
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Spark Therapeutics
    Adeno-associated virus
    AAV
    Leber congenital amaurosis
    RPE65
    Gene therapy
    Gene transfer
    voretigene neparvovec-rzyl
    Retinitis pigmentosa
    Additional relevant MeSH terms:
    Blindness
    Retinal Dystrophies
    Leber Congenital Amaurosis

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title Intervention Control
    Arm/Group Description Bilateral subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2), 1.5x 10e11 vg in a total volume of 0.3ml per eye, administered no fewer than 6 days apart No intervention, no sham; uninjected control group
    Period Title: Overall Study
    STARTED 21 10
    COMPLETED 20 9
    NOT COMPLETED 1 1

    Baseline Characteristics

    Arm/Group Title Intervention Control Total
    Arm/Group Description Bilateral subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2), 1.5x 10e11 vg in a total volume of 0.3ml per eye, administered no fewer than 6 days apart Control group did not receive voretigene neparvovec-rzyl. The control group became eligible to receive voretigene neparvovec-rzyl 1 year after their baseline evaluations, provided they still met all eligibility criteria. Total of all reporting groups
    Overall Participants 21 10 31
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    14.7
    (11.8)
    15.9
    (9.5)
    15.1
    (10.9)
    Age, Customized (Count of Participants)
    <10 years old
    9
    42.9%
    4
    40%
    13
    41.9%
    ≥10 years old
    12
    57.1%
    6
    60%
    18
    58.1%
    Sex: Female, Male (Count of Participants)
    Female
    12
    57.1%
    6
    60%
    18
    58.1%
    Male
    9
    42.9%
    4
    40%
    13
    41.9%
    Ethnicity (NIH/OMB) (Count of Participants)
    Hispanic or Latino
    5
    23.8%
    1
    10%
    6
    19.4%
    Not Hispanic or Latino
    16
    76.2%
    9
    90%
    25
    80.6%
    Unknown or Not Reported
    0
    0%
    0
    0%
    0
    0%
    Race (NIH/OMB) (Count of Participants)
    American Indian or Alaska Native
    2
    9.5%
    1
    10%
    3
    9.7%
    Asian
    3
    14.3%
    2
    20%
    5
    16.1%
    Native Hawaiian or Other Pacific Islander
    0
    0%
    0
    0%
    0
    0%
    Black or African American
    2
    9.5%
    0
    0%
    2
    6.5%
    White
    14
    66.7%
    7
    70%
    21
    67.7%
    More than one race
    0
    0%
    0
    0%
    0
    0%
    Unknown or Not Reported
    0
    0%
    0
    0%
    0
    0%
    Multi-luminance Mobility Test (MLMT), bilateral, passing at a lux level of < 125 or ≥ 125 lux (Count of Participants)
    Lowest passing light level of < 125 lux
    12
    57.1%
    4
    40%
    16
    51.6%
    Lowest passing light level of ≥ 125 lux
    9
    42.9%
    6
    60%
    15
    48.4%

    Outcome Measures

    1. Primary Outcome
    Title Multi-luminance Mobility Testing (MLMT), Bilateral
    Description The MLMT measures changes in functional vision, as assessed by the ability to navigate a course accurately and at a reasonable pace at different levels of environmental illumination. MLMT was assessed using both eyes at 1 or more of 7 levels of illumination, ranging from 400 lux (a brightly lit office) to 1 lux (a moonless summer night). Each light level was assigned a score code ranging from 0 to 6. A higher score indicated that a subject was able to pass the MLMT at a lower light level. A score of -1 was assigned to those who could not pass MLMT at 400 lux. The MLMT of each subject was videotaped and assessed by independent graders. The MLMT score was determined by the lowest light level at which the subject was able to pass the MLMT. The MLMT score change was defined as the difference between the score at Baseline and the score at Year 1. A positive MLMT score change from Baseline to Year 1 visit indicated that the subject was able to complete the MLMT at a lower light level.
    Time Frame One year (change from baseline)

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Intervention Control
    Arm/Group Description Bilateral, subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2) No intervention, no sham; uninjected control group
    Measure Participants 21 10
    Mean (Standard Deviation) [Score Change in Light Levels]
    1.8
    (1.1)
    0.2
    (1.0)
    2. Secondary Outcome
    Title Full-field Light Sensitivity Threshold (FST) Testing: White Light
    Description Measures the light sensitivity of the entire visual field by recording the luminance at which a subject reliably reports seeing the dimmest flash.
    Time Frame One year (change from baseline)

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Intervention Control
    Arm/Group Description Bilateral, subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2) No intervention, no sham; uninjected control group
    Measure Participants 21 10
    Mean (Standard Error) [log10(cd.s/(m^2))]
    -2.08
    (0.29)
    0.04
    (0.44)
    3. Secondary Outcome
    Title Multi-luminance Mobility Testing (Monocular)
    Description The MLMT measures changes in functional vision, as assessed by the ability to navigate a course accurately and at a reasonable pace at different levels of environmental illumination. MLMT was assessed using the first eye at 1 or more of 7 levels of illumination, ranging from 400 lux (a brightly lit office) to 1 lux (a moonless summer night). Each light level was assigned a score code ranging from 0 to 6. A higher score indicated that a subject was able to pass the MLMT at a lower light level. A score of -1 was assigned to those who could not pass MLMT at 400 lux. The MLMT of each subject was videotaped and assessed by independent graders. The MLMT score was determined by the lowest light level at which the subject was able to pass the MLMT. The MLMT score change was defined as the difference between the score at Baseline and the score at Year 1. A positive MLMT score change from Baseline to Year 1 visit indicated that the subject was able to complete the MLMT at a lower light level.
    Time Frame One year (change from baseline)

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Intervention Control
    Arm/Group Description Bilateral, subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2) No intervention, no sham; uninjected control group
    Measure Participants 21 10
    Mean (Standard Deviation) [Score Change in Light Levels]
    1.9
    (1.2)
    0.2
    (0.6)
    4. Secondary Outcome
    Title Visual Acuity
    Description Measurement of the sharpness of vision, determined by the ability to read letters on a standardized chart from a specified distance.
    Time Frame One year (change from baseline)

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Intervention Control
    Arm/Group Description Bilateral, subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2) No intervention, no sham; uninjected control group
    Measure Participants 21 10
    Mean (Standard Error) [LogMAR]
    -0.16
    (0.07)
    0.01
    (0.10)

    Adverse Events

    Time Frame 1 year post administration (Intervention group), 1 year post baseline (Control group)
    Adverse Event Reporting Description The safety population (n=29) includes all subjects who received injection in either eye for the intervention group and all control group subjects who did not withdraw, or were not withdrawn, prior to any of the following people knowing the treatment assignment: the subject, parent, Principal Investigator, or Medical Monitor.
    Arm/Group Title Intervention Control
    Arm/Group Description Bilateral subretinal injection of voretigene neparvovec-rzyl (AAV2-hRPE65v2), 1.5x 10e11 vg in a total volume of 0.3ml per eye, administered no fewer than 6 days apart No intervention, no sham; uninjected control group
    All Cause Mortality
    Intervention Control
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/21 (0%) 0/10 (0%)
    Serious Adverse Events
    Intervention Control
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 2/20 (10%) 0/9 (0%)
    Nervous system disorders
    Convulsion 1/20 (5%) 1 0/9 (0%) 0
    Surgical and medical procedures
    Adverse Drug Reaction 2/20 (10%) 2 0/9 (0%) 0
    Other (Not Including Serious) Adverse Events
    Intervention Control
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 13/20 (65%) 1/9 (11.1%)
    Eye disorders
    Cataract 3/20 (15%) 4 0/9 (0%) 0
    Elevated intraocular pressure 4/20 (20%) 5 0/9 (0%) 0
    Retinal tear 2/20 (10%) 2 0/9 (0%) 0
    Eye inflammation 2/20 (10%) 6 0/9 (0%) 0
    Conjunctival cyst 1/20 (5%) 1 0/9 (0%) 0
    Conjunctivis viral 1/20 (5%) 1 0/9 (0%) 0
    Eye irritation 1/20 (5%) 1 0/9 (0%) 0
    Eye pain 1/20 (5%) 1 0/9 (0%) 0
    Eye pruritus 1/20 (5%) 1 0/9 (0%) 0
    Eye swelling 1/20 (5%) 1 0/9 (0%) 0
    Foreign body sensation in eyes 1/20 (5%) 1 0/9 (0%) 0
    Iritis 1/20 (5%) 1 0/9 (0%) 0
    Macular hole/degeneration 1/20 (5%) 2 0/9 (0%) 0
    Maculopathy/ epiretinal membrane 1/20 (5%) 2 0/9 (0%) 0
    Pseudopapilledema 1/20 (5%) 1 0/9 (0%) 0
    Retinal hemorrhage 1/20 (5%) 1 0/9 (0%) 0
    Photopsia 0/20 (0%) 0 1/9 (11.1%) 1

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Clinical Director
    Organization Spark Therapeutics
    Phone
    Email clinicaltrials@sparktx.com
    Responsible Party:
    Spark Therapeutics
    ClinicalTrials.gov Identifier:
    NCT00999609
    Other Study ID Numbers:
    • AAV2-hRPE65v2-301
    First Posted:
    Oct 22, 2009
    Last Update Posted:
    Dec 13, 2021
    Last Verified:
    Dec 1, 2021